• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical Pediatric Endocrinology >Therapeutic Efficacy and Safety of GH in Japanese Children with Down Syndrome Short Stature Accompanied by GH Deficiency
【24h】

Therapeutic Efficacy and Safety of GH in Japanese Children with Down Syndrome Short Stature Accompanied by GH Deficiency

机译：生长激素缺乏症对日本唐氏综合症矮小儿童的生长激素治疗疗效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, we investigated the effects of GH treatment in children with Down syndrome who had been diagnosed with GH deficiency (GHD). A total of 20 subjects were investigated in this study. Fourteen Down syndrome children (5 boys and 9 girls) with short stature due to GHD were treated with GH at Okayama Red Cross General Hospital, and 6 Down syndrome children (4 boys and 2 girls) with short stature due to GHD were registered in the Pfizer International Growth Database (KIGS). Height SD score (SDS) increased throughout the three-year GH treatment period. The overall mean height SDS increased from -3.5 at baseline to -2.5 after 3 yr of treatment. The mean change in height SDS during these 3 yr was 1.1. In addition, height assessment of SD score based on Down syndrome-specific growth data in the Japanese population revealed that the height SDS (Down syndrome) also increased across the 3-yr GH treatment period. The mean change in height SDS (Down syndrome) during these three years was 1.3. GH therapy was effective for Down syndrome short stature accompanied by GHD, and no new safety concerns were found in this study.
机译：在这项研究中，我们调查了GH治疗对诊断为GH缺乏症（GHD）的唐氏综合症儿童的影响。本研究共调查了20名受试者。冈山市红十字会总医院对GH矮小的唐氏综合症儿童14例（男5例，女孩9例）进行了GH的治疗。辉瑞国际成长数据库（KIGS）。在三年的GH治疗期间，身高SD评分（SDS）有所提高。治疗3年后，总体平均身高SDS从基线的-3.5增加到-2.5。在这3年中，身高SDS的平均变化为1.1。此外，基于日本人群唐氏综合症特定生长数据的SD评分身高评估显示，在3年的GH治疗期间，身高SDS（唐氏综合症）也有所增加。在这三年中，身高SDS（唐氏综合症）的平均变化为1.3。 GH疗法对于伴有GHD的唐氏综合症矮小症有效，并且在这项研究中未发现新的安全隐患。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号